ATE205254T1 - Transformierender wachstumsfaktor alpha h1 - Google Patents

Transformierender wachstumsfaktor alpha h1

Info

Publication number
ATE205254T1
ATE205254T1 AT94916791T AT94916791T ATE205254T1 AT E205254 T1 ATE205254 T1 AT E205254T1 AT 94916791 T AT94916791 T AT 94916791T AT 94916791 T AT94916791 T AT 94916791T AT E205254 T1 ATE205254 T1 AT E205254T1
Authority
AT
Austria
Prior art keywords
alpha
polypeptide
growth factor
transforming growth
factor alpha
Prior art date
Application number
AT94916791T
Other languages
English (en)
Inventor
Paul S Meissner
Rebecca Fuldner
Mark D Adams
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE205254T1 publication Critical patent/ATE205254T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94916791T 1994-03-08 1994-05-12 Transformierender wachstumsfaktor alpha h1 ATE205254T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/208,008 US5633147A (en) 1994-03-08 1994-03-08 Transforming growth factor αH1
PCT/US1994/005476 WO1995024466A1 (en) 1994-03-08 1994-05-12 Transforming growth factor alpha h1

Publications (1)

Publication Number Publication Date
ATE205254T1 true ATE205254T1 (de) 2001-09-15

Family

ID=22772852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916791T ATE205254T1 (de) 1994-03-08 1994-05-12 Transformierender wachstumsfaktor alpha h1

Country Status (14)

Country Link
US (1) US5633147A (de)
EP (2) EP1063293A3 (de)
JP (1) JPH09509846A (de)
KR (1) KR970701776A (de)
CN (1) CN1087344C (de)
AT (1) ATE205254T1 (de)
AU (1) AU681406B2 (de)
CA (1) CA2184583A1 (de)
DE (1) DE69428214T2 (de)
DK (1) DK0759067T3 (de)
ES (1) ES2161246T3 (de)
PT (1) PT759067E (de)
WO (1) WO1995024466A1 (de)
ZA (1) ZA943465B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020188110A1 (en) * 1994-03-08 2002-12-12 Human Genome Sciences, Inc. Transforming growth factor alpha HI
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6074839A (en) 1994-03-08 2000-06-13 Human Genome Sciences, Inc. Transforming growth factor αHI
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6410506B1 (en) * 1995-05-19 2002-06-25 Human Genome Sciences, Inc. Transforming growth factor α HII
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7294482B2 (en) * 1998-11-19 2007-11-13 Millennium Pharmaceuticals, Inc. EGF-like nucleic acids
AU2153500A (en) * 1998-11-19 2000-06-05 Millennium Pharmaceuticals, Inc. Egf-like nucleic acids and polypeptides and uses thereof
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US20020099008A1 (en) 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
DE60035192T2 (de) 1999-04-26 2008-02-14 Applied Protein Sciences, LLC, Mountain View Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
CA2380635A1 (en) * 1999-08-19 2001-02-22 Applied Protein Sciences, Llc Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7273751B2 (en) * 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2002083850A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO2004089357A2 (en) * 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AU2008312457B2 (en) * 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI890312L (fi) * 1988-01-25 1989-07-26 Oncogen Amfiregulin: ett nytt bifunktionellt tillvaext modulerande glykoprotein.
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein

Also Published As

Publication number Publication date
ES2161246T3 (es) 2001-12-01
KR970701776A (ko) 1997-04-12
AU6835094A (en) 1995-09-25
EP1063293A3 (de) 2001-07-11
PT759067E (pt) 2002-02-28
WO1995024466A1 (en) 1995-09-14
CA2184583A1 (en) 1995-09-14
EP0759067B1 (de) 2001-09-05
ZA943465B (en) 1995-11-20
EP1063293A2 (de) 2000-12-27
JPH09509846A (ja) 1997-10-07
US5633147A (en) 1997-05-27
DE69428214T2 (de) 2002-06-27
DK0759067T3 (da) 2001-10-22
DE69428214D1 (de) 2001-10-11
AU681406B2 (en) 1997-08-28
EP0759067A1 (de) 1997-02-26
CN1087344C (zh) 2002-07-10
CN1143386A (zh) 1997-02-19
EP0759067A4 (de) 1997-10-22

Similar Documents

Publication Publication Date Title
DE69428214D1 (de) Transformierender wachstumsfaktor alpha h1
DK0751992T3 (da) Karendotelvækstfaktor 2
DE69333802D1 (de) Äusseres membranprotein von haemophilus
NL300106I2 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
HUP0103758A2 (hu) Neurotróf faktorok
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
EP0787802A3 (de)
DE68929551D1 (de) Menschliche DNase
DK1165791T3 (da) Humant cytokin som zalpha-receptor-ligand og anvendelse deraf
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
CA2096010A1 (en) Recombinant feline coronavirus s proteins
EP0209543A4 (de) Peptidfragmente menschlicher apolipoproteine, typspezifische antikörper und verwendungsverfahren.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
EP0369816A3 (de) Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
ATE119914T1 (de) Peptide, deren verwendung als immuno- suppressanten und verfahren zu deren herstellung.
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
ZA944039B (en) Superoxide dismutase-4
EP0780472A3 (de) Stress Proteine
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
WO2001075008A3 (fr) Nouveau polypeptide, protéine hélicase-anneau-hélicase 11, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee